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Two recent reports describe promising, highly efficient methods to modify genes in pluripotent stem cells
using zinc finger nuclease (ZFN)-mediated (Soldner et al., 2011) or helper-dependent adenovirus (HDAdV)-
mediated (Liu et al., 2011b) gene modification. These technical developments will have far ranging effects
on the rapidly growing field of regenerative medicine.The reprogramming of human adult fibro-
blasts from patients with specific dis-
eases into induced pluripotent stem cells
(hiPSCs) capable of making any tissue of
the body has begun a new era of regener-
ative medicine. However, the ability to
correct or insert mutated genes or selec-
tively target promoter regions remains a
crucial but elusive goal in this field. Re-
cently the Jaenisch and Belmonte groups
produced and characterized hiPSCs from
patients with Parkinson’s disease (PD)
(Soldner et al., 2009) and progeria (Liu
et al., 2011a), respectively. In these and
other related studies, it has been chal-
lenging to select appropriate ‘‘normal’’
control lines with which to compare the
patient-derived lines, due to large interline
variation. In these circumstances, an ideal
control would be to examine pairs of
isogenic lines, where the mutation in
question is either inserted or removed,
and the resulting cells compared to the
parental line. Now, the Jaenisch and Bel-
monte groups extend their previous work
and directly address this central issue
by using two different gene targeting
approaches—zinc finger nuclease (ZFN)
technology (Soldner et al., 2011), and
helper-dependent adenoviral vectors
(HDAdV) (Liu et al., 2011b), to generate
isogenic sets of cells.
PD is an adult onset neurodegenerative
disorder primarily characterized by a loss
of dopamine neurons, but it also encom-
passes many other pathological changes.
While mainly sporadic, there are familial
forms of PD that involve missense muta-
tions, duplication, or triplication of the
a-Synuclein (a-SYN) gene, and which
have provided the basis for many mouse
models of the disease (Dawson et al.,
2010). However, the mutant mice do not
show all the phenotypes of the human
disease, most notably the hallmark lossof dopamine neurons. While human plu-
ripotent stem cells (hPSCs) can be differ-
entiated to dopamine neurons, and en-
forcing overexpression of mutant a-SYN
in this system can recapitulate some
aspects of PD, these models randomly
insert multiple copies of the pathogenic
gene under constitutive promoters,
causing abnormally high levels of protein
expression in a non-cell-specific way
(Schneider et al., 2007). Ideally, a single
copy of the mutant a-SYN would be in-
serted or deleted from its endogenous
location, but traditional homologous re-
combination methods are inefficient and
difficult to achieve for hPSCs (Zwaka
and Thomson, 2003). ZFN technology
can be used to produce precise, targeted
double-stranded breaks (DSBs) in PSCs,
thus significantly increasing the efficiency
of gene targeting (Hockemeyer et al.,
2009).
Using this technology, Jaenisch and
colleagues generated isogenic pairs of
human embryonic stem cells (hESCs)
and iPSCs (Soldner et al., 2011). First
they introduced the A53T (G209A nucleo-
tide) or E46K (G188A nucleotide) SYN
mutations (commonly found in familial
PD) into the genome of two control
hESC lines. They utilized a panel of donor
vectors in this effort, including (1) LoxP-
flanked donor vectors containing the
mutation and either a positive or a posi-
tive-negative selection marker, (2) donor
vectors without any selection marker,
and (3) single-stranded oligodeoxynu-
cleotides (ssODN). Although the positive
or positive-negative selection method
gave a higher targeting efficiency (1.04%
to 9.75%) than one with no selection
marker or ssODNs (0.42% to 0.83%),
all donor sources were capable of intro-
ducing the desired mutation into the
a-SYN locus. Next, the authors showedCell Stem Cethat, even with no selection marker, the
donor sequence could be used to repair
the G209A mutation in the genome of
iPSCs derived from fibroblasts isolated
from a PD patient carrying this mutation.
Finally, risk of genetic instability mediated
by the DSBs was assessed by analyzing
copy number variation (CNV) and whole-
genome expression profiling in pairs of
isogenic cell lines. This examination re-
vealed that no substantial changes were
introduced before or after ZFN-mediated
gene targeting.
This study highlights two exciting
advances for gene targeting and disease
modeling using hPSCs. First, successful
targeting with no selection marker or
ssODN reduces the time it takes to
make lines and does not leave any molec-
ular footprint (e.g., LoxP) in the corrected
cells (Table 1). Second, as highlighted
above, the ability to knock in or knock
out pathogenic genes allows the genera-
tion of isogenic pairs of hiPSCs. Com-
bined, these two traits appear to solve
the issue of selection of candidate control
lines, and therefore offer an opportunity to
improve in vitro disease modeling efforts
within a defined genetic background.
However, multiple paired isogenic lines
will be required to assess the effects of
other genes that may modify pathogen-
esis due to individual variation (i.e., differ-
ential expression of responsive genes
and other genetic modifiers). Further-
more, while this study was a technical
tour de force, it did not discuss whether
the a-SYN mutation, either endogenously
expressed or introduced, resulted in
any PD-related phenotype in dopamine
neurons derived from the isogenic lines,
as seen in previous overexpression
studies (Schneider et al., 2007).
Hutchinson-Gilford progeria syndrome
(HGPS, or progeria) is a disease causedll 9, August 5, 2011 ª2011 Elsevier Inc. 93
Table 1. Comparison between Zinc Finger Nuclease (ZFN)-Mediated and
Helper-Dependent Adenovirus (HDAdV)-Mediated Gene Targeting Methods
Gene Targeting Method Zinc Finger Nuclease Helper-Dependent Adenovirus
Length of homology arm 0.8 to 1 kb 10 to 15 kb
Cloning time shorter longer




Starting cell number 10 3 106 cells 3 3 106 cells





35% to 46% in LMNA locus
Molecular footprint
(e.g., FRT or LoxP)
no yes
Source commercially available open source




cell lines by targeting
endogenous promoter region;
gain-of-function study
a These efficiencies could be locus dependent. To compare relative efficiencies, both methods
would need to be used in parallel to target the same locus.
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Previewsby mutations in the Lamin A (LMNA) gene,
which result in the accumulation of a
truncated form of the protein termed pro-
gerin. The buildup of progerin leads to
a premature aging syndrome, exhibited
by increased senescence-associated-b-
galactosidase (SA-b-Gal) staining and
dysmorphic nuclei in patient smooth
muscle cells, among other symptoms
(Burtner and Kennedy, 2010). Two fasci-
nating iPSC models of this disease have
been published in which patient fibro-
blasts exhibited a reversal of age-related
changes upon reprogramming, but recur-
rence of the aging phenotype upon sub-
sequent differentiation (Zhang et al.,
2011; Liu et al., 2011a). However, neither
of these papers demonstrated correction
of the mutation and any subsequent
phenotype. To extend their findings in
this direction, Belmonte and colleagues
pursued an alternate gene targeting
approach by utilizing HDAdV to perform
classic homologous recombination (Liu
et al., 2011b). HDAdV can contain long
inserts (up to 37 kb), which provides great
flexibility for the size of homology arms
and a wide range of choices for the pro-
moters and selection markers. Further-
more, infection levels with HDAdV are an
order of magnitude greater than normal
transfection methods, which leads to a
higher efficiency of hPSC targeting, and94 Cell Stem Cell 9, August 5, 2011 ª2011 Eltherefore allows for a relatively smaller
starting number of cells needed to yield
modified lines. The authors showed that
HDAdVs containing wild-type 21.7 kb
sequences could correct the C1824T
nucleotide mutation, leading to restora-
tion of SA-b-Gal staining, reversion of
dysmorphic nuclei to normal, and ceased
expression of progerin, even after differ-
entiation to smooth muscle cells. Addi-
tionally, they demonstrated that a single
type of HDAdVs could be used for correc-
tion of multiple mutations in the LMNA
locus by successfully targeting another
mutation (A1733T nucleotide) in LMNA,
likely due to the long homology arms.
Given that LMNA is a silent locus in
hiPSCs, the efficiency of gene targeting
was extremely high (35% to 46%).
Also, CNV analysis and gene expression
profiling suggested that HDAdV-medi-
ated gene targeting did not alter genetic
integrity. Although cloning of long homol-
ogous arms and generation of HDAdV are
tricky technical methods, and a molecular
footprint (e.g., FRT) is left on the locus
after excision of the selection marker,
this study emphasizes the potential utility
of the high efficiency that accompanies
HDAdV technology. More importantly,
this work offers a proof of principle that
a disease-associated phenotype can be
reversed in patient-derived cells aftersevier Inc.genetic modification. However, only one
target was chosen, so now it will be of
great interest to see if loci other than
LMNA are equally susceptible to this
type of gene correction.
Each of these novel techniques offers
distinct advantages and disadvantages,
as summarized in Table 1. ZFN tech-
nology would perhaps be the better
choice for generating isogenic cell lines
with no molecular footprint, whereas
HDAdV provides a robust technique to
insert a reporter gene into an endogenous
promoter region. Whichever is used,
gene editing methods such as these will
enable more precise cell models of
human disease to be developed. Further-
more, they may also enable human cell
therapy studies with iPSC lines through
specific engineering of the cells to
release therapeutic proteins, marker pro-
teins, or suicide genes. This technology
may also be used to correct disease
mutations prior to transplantation. These
are certainly very exciting times for the
stem cell field.
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